Secretory phospholipase A2: A multifaceted family of proatherogenic enzymes

Current Cardiology Reports

Volumn 11, Issue 6, 2009, Pages 445-451

  Rosenson, Robert S ^a   Gelb, Michael H ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

A 001; A 002; ANGIOTENSIN II; APOLIPOPROTEIN E; ATORVASTATIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LY 333013; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLSERINE; PLACEBO; PRAVASTATIN; PROTEIN KINASE B; PROTEIN KINASE C; PROTEOGLYCAN; S 3013; SECRETORY PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VARESPLADIB; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; VERY LOW DENSITY LIPOPROTEIN; VITRONECTIN RECEPTOR; ACETIC ACID DERIVATIVE; INDOLE DERIVATIVE; LIPOPROTEIN; PHOSPHOLIPID;

ACUTE CORONARY SYNDROME; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CATALYSIS; CD4 CD8 RATIO; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG POTENTIATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME RELEASE; ENZYME STRUCTURE; HUMAN; HYDROLYSIS; ISCHEMIC HEART DISEASE; LIPOLYSIS; LOW DRUG DOSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; ANIMAL; ARTERIOSCLEROSIS; DISEASE COURSE; DRUG ANTAGONISM; ENZYMOLOGY; INFLAMMATION; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOPHYSIOLOGY;

ACETIC ACIDS; ANIMALS; ARTERIOSCLEROSIS; DISEASE PROGRESSION; HUMANS; INDOLES; INFLAMMATION; LIPOPROTEINS; MICE; OXIDATIVE STRESS; PHOSPHOLIPASES A2, SECRETORY; PHOSPHOLIPIDS;

EID: 72849108951     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-009-0064-2     Document Type: Review

References (53)

1. M. Kimura-Matsumoto Y. Ishikawa K. Komiyama, et al. 2008 Expression of secretory phospholipase A2s in human atherosclerosis development Atherosclerosis 196 81 91 10.1016/j.atherosclerosis.2006.08.062 1:CAS:528: DC%2BD1cXpt12nsQ%3D%3D 17353016
2. G. Lambeau M.H. Gelb 2008 Biochemistry and physiology of mammalian secreted phospholipases A2 Annu Rev Biochem 77 495 520 10.1146/annurev.biochem. 76.062405.154007 1:CAS:528:DC%2BD1cXos1ekurk%3D 18405237
3. J. Burke E. Dennis 2009 Phospholipase A2 biochemistry Cardiovasc Drugs Ther 23 49 59 10.1007/s10557-008-6132-9 1:CAS:528:DC%2BD1MXotVyrtQ%3D%3D 18931897
4. M.H. Gelb E. Valentin F. Ghomashchi, et al. 2000 Cloning and recombinant expression of a structurally novel human secreted phospholipase A2 J Biol Chem 275 39823 39826 10.1074/jbc.C000671200 1:CAS:528:DC%2BD3MXhsFejtg%3D%3D 11031251 (Pubitemid 32064600)
5. E. Valentin G. Lambeau 2000 Increasing molecular diversity of secreted phospholipases A2 and their receptors and binding proteins Biochimica et Biophysica Acta 1488 59 70 1:CAS:528:DC%2BD3cXotlGisbc%3D 11080677
6. D.L. Scott S.P. White J.L. Browning, et al. 1991 Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate Science 254 1007 1010 10.1126/science.1948070 1:CAS:528:DyaK38Xht1ert7k%3D 1948070
7. Y.H. Pan B.-Z. Yu A.G. Singer, et al. 2002 Crystal structure of human group X secreted phospholipase A2. Electrostatically neutral interfacial binding surface targets zwitterionic membranes J Biol Chem 277 29086 29093 10.1074/jbc.M202531200 1:CAS:528:DC%2BD38XmsVKjsL4%3D 12161451
8. J.A. Tischfield Y.R. Xia D.M. Shih, et al. 1996 Low-molecularweight, calcium-dependent phospholipase A2 genes are linked and map to homologous chromosome regions in mouse and human Genomics 32 328 333 10.1006/geno.1996.0126 1:CAS:528:DyaK28XhvVGmt7s%3D 8838795 (Pubitemid 26094335)
9. T. Ono H. Tojo S. Kuramitsu, et al. 1988 Purification and characterization of a membrane-associated phospholipase A2 from rat spleen. Its comparison with a cytosolic phospholipase A2 s-1 J Biol Chem 263 5732 5738 1:CAS:528:DyaL1cXitFyjuro%3D 3356705
10. S.A. Beers A.G. Buckland R.S. Koduri, et al. 2002 The antibacterial properties of secreted phospholipases A2. A major physiological role for the group IIA enzyme that depends on the very high pi of the enzyme to allow penetration of the bacterial cell wall J Biol Chem 277 1788 1793 10.1074/jbc.M109777200 1:CAS:528:DC%2BD38XosFeitQ%3D%3D 11706041 (Pubitemid 34968750)
11. S. Bezzine J.G. Bollinger A.G. Singer, et al. 2002 On the binding preference of human groups IIA and X phospholipases A2 for membranes with anionic phospholipids J Biol Chem 277 48523 48534 10.1074/jbc.M203137200 1:CAS:528:DC%2BD38Xptlegt7o%3D 12244093 (Pubitemid 35470813)
12. A.G. Singer F. Ghomashchi C. Le Calvez, et al. 2002 Interfacial kinetic and binding properties of the complete set of human and mouse groups i, II, V, X, and xii secreted phospholipases A2 J Biol Chem 277 48535 48549 10.1074/jbc.M205855200 1:CAS:528:DC%2BD38Xptlegt7s%3D 12359733 (Pubitemid 35470814)
13. B. Ivandic L.W. Castellani X.P. Wang, et al. 1999 Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2 Arterioscler Thromb Vasc Biol 19 1284 1290 1:CAS:528:DyaK1MXkvFaktb4%3D 10323781
14. K. Hanasaki T. Ono A. Saiga, et al. 1999 Purified group X secretory phospholipase A2 induced prominent release of arachidonic acid from human myeloid leukemia cells J Biol Chem 274 34203 34211 10.1074/jbc.274.48.34203 1:CAS:528:DyaK1MXnslOksL0%3D 10567392
15. U.J. Tietge C. Maugeais W. Cain, et al. 2000 Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I J Biol Chem 275 10077 10084 10.1074/jbc.275.14.10077 1:CAS:528:DC%2BD3cXisFWjs78%3D 10744687 (Pubitemid 30202058)
16. K.-I. Higashino Y. Yokota T. Ono, et al. 2002 Identification of a soluble form phospholipase A2 receptor as a circulating endogenous inhibitor for secretory phospholipase A2 J Biol Chem 277 13583 13588 10.1074/jbc.M108752200 1:CAS:528:DC%2BD38XjsFWgu7s%3D (Pubitemid 34967956)
17. E. Hurt-Camejo G. Camejo 1997 Potential involvement of type II phospholipase A2 in atherosclerosis Atherosclerosis 132 1 8 10.1016/S0021- 9150(97)00085-3 1:CAS:528:DyaK2sXkvFOntL8%3D 9247353 (Pubitemid 27306733)
18. E. Hurt-Camejo S. Andersen R. Standal, et al. 1997 Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries: Activity of the isolated enzyme on low-density lipoproteins Arterioscler Thromb Vasc Biol 17 300 309 1:CAS:528:DyaK2sXhvFCjsr0%3D 9081685
19. C.R. Wooton-Kee B.B. Boyanovsky M.S. Nasser, et al. 2004 Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation Arterioscler Thromb Vasc Biol 24 762 767 10.1161/01.ATV.0000122363.02961.c1 1:CAS:528: DC%2BD2cXisVGmt74%3D 14962950 (Pubitemid 38451617)
20. C. Flood M. Gustafsson R.E. Pitas, et al. 2004 Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoproteincontaining human apolipoprotein B100 Arterioscler Thromb Vasc Biol 24 564 570 10.1161/01.ATV.0000117174.19078.85 1:CAS:528:DC%2BD2cXhvFOju7k%3D 14726411 (Pubitemid 38326154)
21. P. Sartipy G. Camejo L. Svensson, et al. 1999 Phospholipase A2 modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans J Biol Chem 274 25913 25920 10.1074/jbc.274.36.25913 1:CAS:528:DyaK1MXmtVWhtrc%3D 10464335 (Pubitemid 29418628)
22. J.K. Hakala K. Oorni M.O. Pentikainen, et al. 2001 Lipolysis of LDL by human secretory phospholipase A2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans Arterioscler Thromb Vasc Biol 21 1053 1058 1:CAS:528:DC%2BD3MXksVaqu7s%3D 11397719
23. P. Sartipy B. Johansen K. Gasvik, et al. 2000 Molecular basis for the association of group IIA phospholipase A2 and decorin in human atherosclerotic lesions Circ Res 86 707 714 1:CAS:528:DC%2BD3cXitlajtrg%3D 10747008
24. M. Murakami T. Kambe S. Shimbara, et al. 1999 Functional association of type IIA secretory phospholipase A2 with the glycosylphosphatidylinositol- anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway J Biol Chem 274 29927 29936 10.1074/jbc.274.42. 29927 1:CAS:528:DyaK1MXmvVajtr4%3D 10514475 (Pubitemid 29483372)
25. Y. Kleinman E.S. Krul M. Burnes, et al. 1988 Lipolysis of LDL with phospholipase A2 alters the expression of selected ApoB-100 epitopes and the interaction of LDL with cells J Lipid Res 29 729 743 1:CAS:528: DyaL1cXks12jurc%3D 2459282
26. I.N. Gorshkova M. Menschikowski W. Jaross 1996 Alterations in the physiochemical characteristics of low and high density lipoproteins after lipolysis with phospholipase A2. A spin-label study Biochimica et Biophysica Acta 1300 103 113 8652635
27. U.J.F. Tietge D. Pratico T. Ding, et al. 2005 Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress J Lipid Res 46 1604 1614 10.1194/jlr.M400469-JLR200 1:CAS:528:DC%2BD2MXotFamtbo%3D 15897607 (Pubitemid 41099327)
28. B. Rosengren H. Peilot M. Umaerus, et al. 2006 Secretory phospholipase A2 group V: Lesion distribution, activation by arterial proteoglycans, and induction in aorta by a western diet Arterioscler Thromb Vasc Biol 26 1579 1585 10.1161/01.ATV.0000221231.56617.67 1:CAS:528:DC%2BD28XmvFyjurw%3D 16601231 (Pubitemid 44288986)
29. S.A. Karabina I. Brocheriou G. Le Naour, et al. 2006 Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function FASEB J 20 2547 2549 10.1096/fj.06-6018fje 1:CAS:528:DC%2BD28Xht1yntr3M 17077289 (Pubitemid 44953776)
30. L. Gesquiere W. Cho P.V. Subbaiah 2002 Role of group IIa and group V secretory phospholipases A2 in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin Biochemistry 41 4911 4920 10.1021/bi015757x 1:CAS:528: DC%2BD38XitFajtbY%3D 11939786 (Pubitemid 34298658)
31. K. Hanasaki K. Yamada S. Yamamoto, et al. 2002 Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation J Biol Chem 277 29116 29124 10.1074/jbc. M202867200 1:CAS:528:DC%2BD38XmsVKjsLo%3D 12021277
32. N. Leitinger A.D. Watson S.Y. Hama, et al. 1999 Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids Arterioscler Thromb Vasc Biol 19 1291 1298 1:CAS:528:DyaK1MXkvFaktb8%3D 10323782
33. T. Bhattacharyya S.J. Nicholls E.J. Topol, et al. 2008 Relationship of paraoxonase 1 (pon1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk JAMA 299 1265 1276 10.1001/jama.299.11. 1265 1:CAS:528:DC%2BD1cXjsVOmtb8%3D 18349088
34. M. Menschikowski A. Hagelgans B. Heyne, et al. 2005 Statins potentiate the IFN-[gamma]-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and hepg2 hepatoma cells Biochimica et Biophysica Acta 1733 157 171 1:CAS:528:DC%2BD2MXjs1Ohtbg%3D 15863363
35. M. Menschikowski A. Hagelgans U. Hempel, et al. 2004 Glycogen synthase kinase-3[beta] negatively regulates group IIA phospholipase A2 expression in human aortic smooth muscle and hepg2 hepatoma cells FEBS Lett 577 81 86 10.1016/j.febslet.2004.09.067 1:CAS:528:DC%2BD2cXpsFektbk%3D 15527765 (Pubitemid 39452364)
36. D.-W. Park J.R. Kim S.Y. Kim, et al. 2003 Akt as a mediator of secretory phospholipase A2 receptor-involved inducible nitric oxide synthase expression J Immunol 170 2093 2099 1:CAS:528:DC%2BD3sXht12iu7c%3D 12574380
37. M.A. Balboa J. Balsinde M.V. Winstead, et al. 1996 Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages J Biol Chem 271 32381 32384 10.1074/jbc.271.50.32381 1:CAS:528:DyaK2sXit1Khtg%3D%3D 8943302 (Pubitemid 26422280)
38. Y.J. Kim K.P. Kim S.K. Han, et al. 2002 Group V phospholipase A2 induces leukotriene biosynthesis in human neutrophils through the activation of group IVA phospholipase A2 J Biol Chem 277 36479 36488 10.1074/jbc.M205399200 1:CAS:528:DC%2BD38XnsVCjtbo%3D 12124392
39. W.R. Henderson Jr E.Y. Chi J.G. Bollinger, et al. 2007 Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model J Exp Med 204 865 877 10.1084/jem.20070029 1:CAS:528:DC%2BD2sXksFSqurc%3D 17403936 (Pubitemid 46631615)
40. A. Saiga N. Uozumi T. Ono, et al. 2005 Group X secretory phospholipases A2 can induce arachidonic acid release and eicosanoid production without activation of cytosolic phospholipase A2 alpha Prostaglandins Other Lipid Mediat 75 79 89 10.1016/j.prostaglandins.2004.10.001 1:CAS:528:DC%2BD2MXhtleltb8%3D 15789617 (Pubitemid 40248380)
41. S. Bezzine R.S. Koduri E. Valentin, et al. 2000 Exogenously added human group X secreted phospholipase A(2) but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells J Biol Chem 275 3179 3191 10.1074/jbc.275.5.3179 1:CAS:528:DC%2BD3cXhtVygs78%3D 10652303 (Pubitemid 30083017)
42. E. Boilard S.G. Bourgoin C. Bernatchez, et al. 2003 Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human t cells: Role of heparan sulfate proteoglycans FASEB J 17 1068 1080 10.1096/fj.02-0938com 1:CAS:528:DC%2BD3sXksVWisrY%3D 12773489 (Pubitemid 36676393)
43. Saegusa J, Akakura N, Wu CY, et al.: Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins {alpha}v{beta}3 and {alpha}4ta1 and induces proliferation of monocytic cells in an integrin-dependent manner. J Biol Chem 2008, 283:26107-26115.
44. A.S. Antonov F.D. Kolodgie D.H. Munn, et al. 2004 Regulation of macrophage foam cell formation by {alpha}V{beta}3 integrin: potential role in human atherosclerosis Am J Pathol 165 247 258 1:CAS:528:DC%2BD2cXmtFygt7Y%3D 15215180
45. M.A. Bostrom B.B. Boyanovsky C.T. Jordan, et al. 2007 Group V secretory phospholipase A2 promotes atherosclerosis: Evidence from genetically altered mice Arterioscler Thromb Vasc Biol 27 600 606 10.1161/01.ATV.0000257133.60884.44 1:CAS:528:DC%2BD2sXhsVSitbw%3D 17204667 (Pubitemid 46263406)
46. E. Hurt-Camejo U. Olsson O. Wiklund, et al. 1997 Cellular consequences of the association of ApoB lipoproteins with proteoglycans. Potential contribution to atherogenesis Arterioscler Thromb Vasc Biol 17 1011 1017 1:CAS:528:DyaK2sXktlyluro%3D 9194748
47. Y. Ishimoto K. Yamada S. Yamamoto, et al. 2003 Group V and X secretory phospholipase A2s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions Biochimica et Biophysica Acta 1642 129 138 1:CAS:528:DC%2BD3sXot1yqsbk%3D 14572896
48. N.R. Webb M.A. Bostrom S.J. Szilvassy, et al. 2003 Macrophageexpressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice Arterioscler Thromb Vasc Biol 23 263 268 10.1161/01.ATV.0000051701.90972.E5 1:CAS:528:DC%2BD3sXptFyrtw%3D%3D 12588769 (Pubitemid 36231938)
49. B. Boyanovsky N. Webb 2009 Biology of secretory phospholipase A2 Cardiovasc Drugs Ther 23 61 72 10.1007/s10557-008-6134-7 1:CAS:528: DC%2BD1MXotVyrtg%3D%3D 18853244
50. B.B. Boyanovsky D.R. van der Westhuyzen N.R. Webb 2005 Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans J Biol Chem 280 32746 32752 10.1074/jbc.M502067200 1:CAS:528:DC%2BD2MXhtVWiurzM 16040605 (Pubitemid 41368320)
51. H. Fraser C. Hislop R.M. Christie, et al. 2009 Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice J Cardiovasc Pharmacol 53 60 65 10.1097/FJC. 0b013e318195bfbc 1:CAS:528:DC%2BD1MXit1KnsLo%3D
52. Z. Shaposhnik X. Wang J. Trias, et al. 2008 The synergistic inhibition of atherogenesis in ApoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002) J Lipid Res 50 623 629 10.1194/jlr.M800361-JLR200 19029066
53. R.S. Rosenson C. Hislop D. McConnell, et al. 2009 Effects of a selective inhibitor of secretory phospholipase A2 on low density lipoproteins and inflammatory pathways Lancet 373 649 658 10.1016/S0140-6736(09)60403-7 1:CAS:528:DC%2BD1MXitFyrsLc%3D 19231633